The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Zeng, Yanmei ^a   Li, Chenzhong ^a   Guan, Meiping ^a   Zheng, Zongji ^a   Li, Jingjing ^a   Xu, Wenwei ^a   Wang, Ling ^a   He, Feiying ^a   Xue, Yaoming ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

AMPK signaling pathway MAPK signaling pathway; Atherosclerosis; Inflammation; Leukocyte endothelial cell interaction; Sitagliptin

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; COLLAGEN FIBER; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PROTEIN KINASE B; SITAGLIPTIN; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL AORTA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ARCH; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; ATTENUATION; BODY WEIGHT; CELL INTERACTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; ENDOTHELIUM CELL; ENZYME ACTIVATION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; LIPID BLOOD LEVEL; LIPID DIET; MACROPHAGE; MALE; MONOCYTE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; SMOOTH MUSCLE FIBER; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; WESTERN BLOTTING;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DIET, HIGH-FAT; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE PROGRESSION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASES; PYRAZINES; RANDOM ALLOCATION; TRIAZOLES;

EID: 84893162958     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-32     Document Type: Article

References (41)

1. Desai A, Zhao Y, Warren JS. Development of atherosclerosis in Balb/c apolipoprotein E-deficient mice. Cardiovasc Pathol 2008, 17:233-240. 10.1016/j.carpath.2007.10.002, 18402814.
2. Dicker D. DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors. Diabetes Care 2011, 34:S277-S278.
3. Chrysant SG, Chrysant GS. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am J Cardiol 2012, 109:1681-1685. 10.1016/j.amjcard.2012.01.398, 22425330.
4. Yoshiaki Kubota MM, Gen Takagi TI, Sonoko Kirinoki I, Kotoko T. The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. Endocrinol Nutr Metab 2012, 27:1364-1370.
5. Murohara T. Dipeptidyl peptidase-4 inhibitor: another player for cardiovascular protection. J Am Coll Cardiol 2012, 59:277-279. 10.1016/j.jacc.2011.09.050, 22240133.
6. Junichi Matsubara SS, Koichi S, Taishi N, Yukio F, Eiichi A. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein e-deficient mice. J Am Coll Cardiol 2012, 59:265-276. 10.1016/j.jacc.2011.07.053, 22240132.
7. Luft VC, Schmidt MI, Pankow JS, Hoogeveen RC, Couper D, Heiss G, Duncan BB. Dipeptidyl peptidase IV and incident diabetes. Diabetes Care 2010, 33:1109-1111. 10.2337/dc09-1996, 2858185, 20185737.
8. Matheeussen V, Waumans Y, Martinet W, Van Goethem S, Van der Veken P, Scharpé S. Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis. Basic Res Cardiol 2013, 108:350-364.
9. Terasaki M, Nagashima M, Watanabe T, Nohtomi K. Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice. Metab Clin Exp 2012, 61:974-979. 10.1016/j.metabol.2011.11.011, 22225957.
10. Vittone F, Liberman A, Vasic D, Ostertag R, Esser M, Walcher D, Ludwig A, Marx N, Burgmaier M. Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice. Diabetologia 2012, 55(8):2267-2275. 10.1007/s00125-012-2582-5, 22648661.
11. Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, Xu X, Lu B. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011, 124(21):2338-2349. 10.1161/CIRCULATIONAHA.111.041418, 22007077.
12. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010, 59(4):1030-1037. 10.2337/db09-1694, 2844811, 20068138.
13. Ta NN, Li Y, Schuylera CA, Lopes-Virella MF, Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocyte. Atherosclerosis 2010, 213:429-435. 10.1016/j.atherosclerosis.2010.08.064, 20843518.
14. Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2011, 58(2):157-166. 10.1097/FJC.0b013e31821e5626, 3155015, 21558879.
15. Choi MK, Jin QR, Ahn SH, Bae MA, Song IS. Sitagliptin attenuates metformin-mediated AMPK phosphorylation through inhibition of organic cation transporters. Xenobiotica 2010, 40:817-825. 10.3109/00498254.2010.520349, 20863201.
16. Lenski M, Kazakov A, Marx N, Böhm M, Laufs U. Effects of DPP-4 inhibition on cardiac metabolism and function in mice. J Mol Cell Cardiol 2011, 51:906-918. 10.1016/j.yjmcc.2011.08.001, 21871459.
17. Tetsurou I, Emi K, Satoshi I, Akio Y. Soluble CD26/Dipeptidyl Peptidase IV Enhances the Transcription of IL-6 and TNF-ain THP-1 Cells and Monocytes. PLoS ONE 2013, 8:e66520. 10.1371/journal.pone.0066520, 3689814, 23805228.
18. Erdogdu O, Eriksson L, Xu H, Sjoholm T, Zhang Q, Nystrom T. Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways. J Mol Endocrinol 2013, 50:229-241. 10.1530/JME-12-0166, 23343509.
19. Sung JY, Choi HC. Nifedipine inhibits vascular smooth muscle cell proliferation and reactive oxygen species production through AMP-activated protein kinase signaling pathway. Vasc Pharmacol 2012, 56:1-8.
20. Xu Q, Si LY. Protective effects of AMP-activated protein kinase in the cardiovascular system. J Cell Mol Med 2010, 14:2604-2613. 10.1111/j.1582-4934.2010.01179.x, 20874722.
21. Zhang Y, Qiu J, Wang X, Zhang Y, Xia M. AMP-Activated protein kinase suppresses endothelial cell inflammation through phosphorylation of transcriptional coactivator p300. Arterioscler Thromb Vasc Biol 2011, 31:2897-2908. 10.1161/ATVBAHA.111.237453, 21940946.
22. Ou H-C, Hsieh Y-L, Yang N-C, Tsai K-L, Chen K-L, Tsai C-S, Chen I-J. Ginkgo biloba extract attenuates oxLDL-induced endothelial dysfunction via an AMPK-dependent mechanism. J Appl Physiol 2013, 114:274-285. 10.1152/japplphysiol.00367.2012, 23195633.
23. Michell BJ, Chen Z, Tony T, Stapleton D, Katsis F, Power DA. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem 2001, 276(21):17625-17628. 10.1074/jbc.C100122200, 11292821.
24. Zhang K, Meng X, Kong J, Liu F-F, Yang J-M, Gao F, Zhang Y, Zhang C. Simvastatin increases prolyl-4-hydroxylase alpha1 expression in atherosclerotic plaque and ox-LDL-stimulated human aortic smooth muscle cells via p38 MAPK and ERK1/2 signaling. J Mol Cell Cardiol 2013, 65:43-50.
25. Li H, Peng W, Zhuang J, Lu Y, Jian W, Wei Y, Li W, Xu Y. Vaspin attenuates high glucose-induced vascular smooth muscle cells proliferation and chemokinesis by inhibiting the MAPK, PI3K/Akt, and NF-kappaB signaling pathways. Atherosclerosis 2013, 228(1):61-68. 10.1016/j.atherosclerosis.2013.02.013, 23497782.
26. Olejarz W, Bryk D, Zapolska-Downar D, Malecki M, Stachurska A, Sitkiewicz D. Mycophenolic acid attenuates the tumour necrosis factor-alpha-mediated proinflammatory response in endothelial cells by blocking the MAPK/NF-kappaB and ROS pathways. Eur J Clin Invest 2014, 44:54-64. 10.1111/eci.12191, 24134657.
27. Seto SW, Krishna SM, Moran CS, Liu D, Golledge J. Aliskiren limits abdominal aortic aneurysm, ventricular hypertrophy and atherosclerosis in an apolipoprotein E deficient mouse model. Clin Sci (Lond) 2014, Jan 30 [Epub ahead of print].
28. Haeng Park S, Sung Y-Y, Jin Nho K, Kyoung Kim H. Anti-atherosclerotic effects of Polygonum aviculareL. ethanol extract in ApoE knock-out mice fed a Western diet mediated via the MAPK pathway. J Ethnopharmacol 2014, http://dx.doi.org/10.1016/j.jep.2013.12.021.
29. Tang-Feldman YJ, Lochhead SR, Lochhead GR, Yu C, George M, Villablanca AC, Pomeroy C. Murine Cytomegalovirus (MCMV) Infection Upregulates P38 MAP kinase in Aortas of Apo E KO Mice: a Molecular Mechanism for MCMV-Induced Acceleration of Atherosclerosis. J Cardiovasc Transl Res 2013, 6:54-64. 10.1007/s12265-012-9428-x, 23192592.
30. Ervinna N, Mita T, Yasunari E, Azuma K, Tanaka R, Fujimura S. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology 2013, 154:1260-1270. 10.1210/en.2012-1855, 23337530.
31. Picatoste B, Ramírez E, Caro-Vadillo A, Iborra C, Egido J, Tuñón J, Lorenzo T. Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. PLoS One 2013, 8:e78330. 3840053, 24302978.
32. Hemmeryckx B, Swinnen M, Gallacher DJ, Rong Lu H, Roger Lijnen H. Effect of sitagliptin treatment on metabolism and cardiac function in genetic diabetic mice. Eur J Pharmacol 2014, http://dx.doi.org/10.1016/j.ejphar. 2013.12.036i [Epub ahead of print].
33. Engel SS, Golm GT, Shapiro D, Davies MJ, Kaufman KD, Goldstein BJ. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol 2013, 12:3. 10.1186/1475-2840-12-3, 3585887, 23286208.
34. Leibovitz E, Gottlieb S, Goldenberg I, Gevrielov-Yusim N, Matetzky S, Gavish D. Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS). Cardiovasc Diabetol 2013, 12:53. 10.1186/1475-2840-12-53, 3637090, 23537430.
35. Ragbir S, Farmer JA. Dysfunctional high-density lipoprotein and atherosclerosis. Curr Atheroscler Rep 2010, 12(5):343-348. 10.1007/s11883-010-0091-x, 20506005.
36. Sakamoto Y, Oyama J, Ikeda H, Kuroki S, Gondo S, Iwamoto T, Uchida Y, Kodama K, Hiwatashi A, Shimomura M, Taguchi I, Inoue T, Node K, S-DOG Effects of sitagliptin beyond glycemic control: focus on quality of life. Cardiovasc Diabetol 2013, 12:35. 10.1186/1475-2840-12-35, 3606450, 23432786, S-DOG.
37. Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther 2012, 29(1):14-25. 10.1007/s12325-011-0088-z, 22215383.
38. Goto H, Nomiyama T, Mita T, Yasunari E, Azuma K, Komiya K, Arakawa M. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun 2011, 405(1):79-84. 10.1016/j.bbrc.2010.12.131, 21215253.
39. Erdogdu T, Nathanson D, Sjöholm T, Nyström T, Zhang Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 2010, 325:26-35. 10.1016/j.mce.2010.04.022, 20452396.
40. Favaro E, Granata R, Miceli I, Baragli A, Settanni F, Cavallo Perin P, Ghigo E. The ghrelin gene products and exendin-4 promote survival of human pancreatic islet endothelial cells in hyperglycaemic conditions, through phosphoinositide 3-kinase/Akt, extracellular signal-related kinase (ERK)1/2 and cAMP/protein kinase A (PKA) signalling pathways. Diabetologia 2012, 55:1058-1070. 10.1007/s00125-011-2423-y, 3296004, 22231124.
41. Fullerton MD, Steinberg RS, Schertzer JD. Immunometabolism of AMPK in insulin resistance and atherosclerosis. Mol Cell Endocrinol 2013, 366:224-234. 10.1016/j.mce.2012.02.004, 22361321.